Acasti Pharma Inc. (NASDAQ:ACST) price closed higher on Monday, Jan 04, jumping 21.54% above its previous close.
A look at the daily price movement shows that the last close reads $0.32, with intraday deals fluctuated between $0.3200 and $0.4080. The company’s 5Y monthly beta was ticking 0 while its P/E ratio in the trailing 12-month period read 0. Taking into account the 52-week price action we note that the stock hit a 52-week high of $2.54 and 52-week low of $0.17. The stock added 23.44% on its value in the past month.
Acasti Pharma Inc., which has a market valuation of $38.27 Million. The company stock has a Forward Dividend ratio of 0, while the dividend yield is 0. It is understandable that investor optimism is growing ahead of the company’s current quarter results. Analysts tracking ACST have forecast the quarterly EPS to grow by -$0.16 per share this quarter, while the same analysts predict the annual EPS to hit -$0.53 for the year 2021 and up to -$0.35 for 2022. In this case, analysts estimate an annual EPS growth of -0.3% for the year and -0.34% for the next year.
On the technical perspective front, indicators give ACST a short term outlook of Hold on average. Looking at the stock’s medium term indicators we note that it is averaging as a 50% Sell, while an average of long term indicators are currently assigning the stock as 50% Sell.
Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 1 analysts have assigned ACST a recommendation rating as follows: 1 rate it as a Hold; none advise Buy while none analyst(s) assign an Outperform rating. None analyst(s) have tagged the Acasti Pharma Inc. (ACST) stock as Underperform, with none recommending Sell. In general, analysts have rated the stock Hold, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.
If we dive deeper into the stock’s performance we see the positive picture represented by the PEG ratio, currently standing at 0. The overview shows that ACST’s price is at present 34.4% off the SMA20 and 57.72% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 61.57, with weekly volatility standing at 18.35%. The indicator drops to 15.22% when calculated based on the past 30 days. Acasti Pharma Inc. (NASDAQ:ACST)’s beta value is holding at 0, while the average true range (ATR) indicator is currently reading 0.06. Considering analysts have assigned the stock a price target range of $0.25-$0.25 as the low and high respectively, we find the trailing 12-month average consensus price target to be $0.25. Based on this estimate, we see that current price is roughly -37.5% off the estimated low and -37.5% off the forecast high. Investors will no doubt be excited to see the share price rise to $0.25, which is the median consensus price, and at that level ACST would be -37.5% from current price.
Turning out attention to how the Acasti Pharma Inc. stock has performed in comparison to its peers in the industry, here’s what we find: ACST’s stock is +21.54% on the day and -83.05% in the past 12 months, while Dr. Reddy’s Laboratories Ltd (RDY) traded -0.1% in the last session and was positioned +76.9% up on its price 12 months ago. Another comparison is with Teva Pharmaceutical Industries Ltd (TEVA) whose stock price was up 7.15% in the last trading session, and has flourished +13.75% over the past year. Also, Bridgebio Pharma Inc (BBIO) showed uptrend of 21.54% while its price kept floating at -83.05% over the past year. As for Acasti Pharma Inc., the P/E ratio stands at 0 lower than that of Dr. Reddy’s Laboratories Ltd’s at 46.37 and Teva Pharmaceutical Industries Ltd’s 0. Elsewhere in the market, the S&P 500 Index has fell -1.48% in last trading session, with the Dow Jones Industrial also saw a negative session on the day with -1.25%.
An analysis of the Acasti Pharma Inc. (NASDAQ:ACST) stock in terms of its daily trading volume indicates that the 3-month average is 19.08 Million. However, this figure increases on the past 10-day timeline to an average of 38.18 Million.
Curent records show that the company has 96.89 Million in outstanding shares. According to data from Thomson Reuters, insiders’ percentage holdings are 8.64% of outstanding shares while the percentage share held by institutions stands at 1.66%. The stats also highlight that short interest as of December 14, 2020, stood at 506.79 Million shares, which puts the short ratio at the time at 0.04. From this we can glean that short interest is 0.52% of company’s current outstanding shares. Notably, we see that shares short in December fell slightly given the previous month’s figure stood at 543.54 Million. But the +21.54% upside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.
Even if you’re not actively in crypto, you deserve to know what’s actually going on..
Because while leading assets such as Bitcoin (BTC) and Ethereum (ETH) are climbing in value, a select group of public “crypto stocks” are surging right along with them. More importantly, these stocks are outpacing the returns these leading crypto assets are already producing.
Click here to get the full story… along with our long list of backdoor Bitcoin strategies. It’s free.